Next results · Q4 2026Projected
Feb 25, after the close
Thu, Feb 25, 2027in 100 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 24 – Mar 5
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $75.45M
- Revenue, change from a year earlier: Q3 2026 +1.1%, Q2 2026 +7.8%, Q1 2026 −2.6%, Q4 2025 +27.7%
- Net income
- $13.44M
- Net income, change from a year earlier: Q3 2026 −32.7%, Q2 2026 +39.9%, Q1 2026 n/m, Q4 2025 −30.4%
- EPS
- —
- EPS, change from a year earlier: Q3 2026 −35.3%, Q2 2026 +33.3%, Q1 2026 n/m, Q3 2025 −58.5%
Results day
Typical moveA typical move of 10.8% either way
Up after 8 of 12, down after 4.
The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: −24.9% after Q4 2025.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Thursday
- 8 of its last 8
- Session
- after the close
- After quarter end
- 37 to 57 days
- 10-Q filed
- 37 to 38 days
- over its last 8
- 10-K filed
- 58 to 61 days
- over its last 8
Based on 8 prior 10-K filings.
Puma Biotechnology, Inc. · CIK 1401667 · Engraved from SEC EDGAR